Rarebase Names Chris Moxham As Chief Executive Officer
10/04/23, 2:35 PM
Location
palo alto
Industry
biotechnology
health care
therapeutics
artificial intelligence
Rarebase, a platform drug development biotechnology company that is revolutionizing discovering and developing medicines at unprecedented speed, scale, and capital efficiency, today announced that Chris Moxham, Ph.D., President and Chief Scientific Officer of Rarebase, has been named Chief Executive Officer effective immediately. Moxham assumes the CEO position from Rarebase co-founder Onno Faber, who has been appointed to the newly created role of Chief Technology Officer.
Company Info
Location
palo alto, california, united states
Additional Info
Rarebase is enabling a better life for the 400 million people living with rare disease. With a product engine designed to discover treatments for hundreds of monogenic diseases simultaneously, Rarebase is focused on the largest untapped drug discovery opportunity in human health: rare diseases. Rarebase has already uncovered potential treatments for hundreds of rare diseases. The company has also built a “drug-gene atlas” to enable AI-driven drug discovery.